News | September 27, 2022
Novartis unveils new focused strategy
Transformation to pure-play Innovative Medicines company nears completion
Transformation to pure-play Innovative Medicines company nears completion
These moves are designed to strengthen the company’s medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales, and delivery to delight customers
Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
Sandoz is planned to be incorporated in Switzerland and to be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in the US
Biopharma and CROs to benefit from simplified access to global research sites
The company now exceeds the sector benchmark for its overall ESG rating and for all three measures
Medicines, including insulin, to be available in 40 lower-income countries
Condon joins DTx Pharma with more than 20 years of experience in business development, commercial planning, and operations.
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
Subscribe To Our Newsletter & Stay Updated
